Evidence map›Paper›PMID 36335264›Full record

ArticleLeukemia2022

Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.

Mrinal M Patnaik, Amer M Zeidan, Eric Padron, Uwe Platzbecker, David A Sallman, Amy E DeZern, Rafael Bejar, Mikkael Sekeres, Justin Taylor, Richard F Little and 18 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Mrinal M PatnaikDivision of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. Patnaik.mrinal@mayo.edu.ORCID http://orcid.org/0000-0001-6998-662X
Amer M ZeidanSection of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
Eric PadronMalignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-4707-7916
Uwe PlatzbeckerDepartment of Hematology, University of Leipzig, Leipzig, Germany.ORCID http://orcid.org/0000-0003-1863-3239
David A SallmanMalignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0003-0504-8233
Amy E DeZernDivision of Hematologic Malignancies; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
Rafael BejarDivision of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, CA, USA.
Mikkael SekeresSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID http://orcid.org/0000-0003-2009-6524
Justin TaylorSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.ORCID http://orcid.org/0000-0003-4407-6325
Richard F LittleNational Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4091-1699
Jan P BewersdorfLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tae Kon KimDivision of Hematology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-5182-3870
Nina KimNational Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-1809-0417
Christopher S HouriganNational Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Matteo G Dela PortaHumanitas Clinical and Research Center & Humanitas University, Department of Biomedical Sciences, Milan, Italy.
Maximilian StahlDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
David SteensmaNovartis Institute of Blood Research, Boston, MA, USA.
Mina L XuDepartments of Pathology & Laboratory Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.ORCID http://orcid.org/0000-0001-9513-245X
Olatoyosi OdenikeSection of Hematology/Oncology, the University of Chicago Medicine, Chicago, IL, USA.
Hetty CarrawayLeukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-5241-3614
Pierre FenauxHôpital St Louis, Assistance Publique Hôpitaux de Paris, and Université Paris Cité, Paris, France.
Aziz NazhaDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Rami KomrokjiMalignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-1876-5269
Sanam LoghaviDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8980-3202
Zhuoer XieMalignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0003-1266-9804
Robert HasserjianDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7753-0697
Michael SavonaDivision of Hematology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-3763-5504
John M BennettDepartment of Medicine, Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myelodysplastic-Myeloproliferative DiseasesMyeloproliferative DisordersNeoplasmsHumans

Identifiers

PMID36335264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.